

# Bedside newborn phototherapy

Country of origin | United States of America

## Health problem addressed

Global health experts estimate 10% of all newborn mortality can be attributed to jaundice. An excess of the chemical bilirubin in the blood approaches dangerous levels in more than 10% of all newborns. The result can be kernicterus, lifelong disability, severe brain damage, and death, placing an extreme burden on families and communities. Every year in South Asia and Sub-Saharan Africa, more than 5.7 million jaundiced infants need treatment, but do not receive simple phototherapy. There currently is no durable and easy-to-use phototherapy device for rural facilities, so newborn jaundice accounts for 20-33% of admissions to national-level hospitals in developing countries.



## Product description

Bedside Newborn Phototherapy is a device designed to treat jaundice in the mother's room in rural clinics. The double-sided, high-power LED lighting cures the most severe cases of jaundice and dramatically reduces treatment time.

## Developer's claims of products benefits

The device is compact, intuitive, and durable enough to function in the mother's room in a rural clinic, reducing staff workload and promoting breastfeeding. The reduction in treatment time allows resources to be used to treat more infants and allows the family to go home sooner. This can decrease the cost of care, reduce loss of income, reduce exposure to infection, and return mother and baby to the safer home environment to breastfeed. Bedside Newborn Phototherapy's design uses energy-efficient light emitting diodes (LEDs) that last 5 years. It is completely sealed against dust and bugs and has no moving parts, drastically increasing product life.

## Suitability for low-resource settings

In low-resource settings, jaundiced infants referred from rural to higher-level hospitals risk developing permanent brain damage or dying en route. Jaundiced infants are isolated from their mothers in crowded neonatal ICUs, hindering breastfeeding in the critical first days. Bedside phototherapy enables rural hospitals to treat jaundice, which reduces the burden on national-level hospitals to treat more serious conditions. It is produced locally in Vietnam.

## Operating steps

Plug it in and press the button. Fixed two-sided lighting, one intensity setting, and an easy to clean, removable single-infant bassinet make this device hard to use improperly, thereby reducing incidence of ineffective treatment and cross-infection.

## Regulatory status

Used IEC 60601-1:2005 and IEC 60601-2-50:2009 standards to guide the design. Pending assessment by Ministry of Health in Vietnam, recognized by the ASEAN countries. Expected date November 2013.

## Future work and challenges

Production of the first 200 Bedside devices is nearing completion. The first devices were delivered to hospitals in northern Vietnam during Fall 2013; over the following year the remainder will be distributed to Vietnam, Myanmar, Cambodia, Laos, East Timor, the Philippines, Thailand, Malaysia, and Ghana. The plan is to expand to a total of 1,000 Bedside devices, reaching at least 250,000 newborns. The next big challenge is to connect with additional organizations who wish to purchase and distribute the devices worldwide to reach millions of beneficiaries.

## Use and maintenance

**User:** Physician, nurse, family member

**Training:** Provided by supplying organization

**Maintenance:** None

## Environment of use

**Settings:** Rural, urban settings, primary (health post, health center), secondary (general hospital), tertiary (specialized hospital)

**Requirements:** Continuous power supply (90-264VAC), or a 12VDC input typical of car batteries and solar power systems.

## Product specifications

**Dimensions (mm):** 660 x 380 x 495

**Weight (kg):** 11.8

**Consumables:** None

**Life time:** 5 years

**Shelf life:** 5+ years

**Retail Price (USD):** N/A

**List price (USD):** 1500

**Other features:** Mobile, capital equipment

**Year of commercialization:** 2011

**Currently sold in:** Cambodia, East Timor, Ghana, Laos, Malaysia, Myanmar, Philippines, Thailand and more.

## Disclaimer

Eligibility for inclusion in the compendium has been evaluated by WHO and external technical advisers listed in the Acknowledgements. However, the evaluation has been solely based on a limited assessment of data and information submitted in the developers' applications and, where available, of additional sources of evidence, such as literature search results or other publicly available information. There has been no rigorous review for safety, efficacy, quality, applicability, nor cost acceptability of any of the technologies. Therefore, inclusion in the compendium does not constitute a warranty of the fitness of any technology for a particular purpose. Besides, the responsibility for the quality, safety and efficacy of each technology remains with the developer and/or manufacturer. The decision to include a particular technology in the compendium is subject to change on the basis of new information that may subsequently become available to WHO.

WHO will not be held to endorse nor to recommend any technology included in the compendium. Inclusion in the compendium solely aims at drawing stakeholders' attention to innovative health technologies, either existing or under development, with a view to fostering the development and availability of, and/or access to, new and emerging technologies which are likely to be accessible, appropriate and affordable for use in low- and middle-income countries.

WHO does not furthermore warrant or represent that:

1. the list of innovative health technologies is exhaustive or error free; and/or that
2. the technologies which are included in the compendium will be embodied in future editions of the compendium; and/or that
3. the use of the technologies listed is, or will be, in accordance with the national laws and regulations of any country, including but not limited to patent laws; and/or that
4. any product that may be developed from the listed technologies will be successfully commercialized in target countries or that WHO will finance or otherwise support the development or commercialization of any such product.

WHO disclaims any and all liability and responsibility whatsoever for any injury, death, loss, damage, use of personal data, or other prejudice of any kind whatsoever that may arise as a result of, or in connection with, the procurement, distribution and/or use of any technology embodied in the compendium, or of any resulting product and any future development thereof.

Developers whose technology has been included in the compendium shall not, in any statement of an advertising, commercial and/or promotional nature, refer to their participation and/or inclusion in the compendium. In no case shall the latter use the WHO name and/or the emblem, or any abbreviation thereof, in relation to their business or otherwise.